Shepherd Financial Partners LLC Purchases 46 Shares of Cencora, Inc. (NYSE:COR)

Shepherd Financial Partners LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 0.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,441 shares of the company’s stock after buying an additional 46 shares during the period. Shepherd Financial Partners LLC’s holdings in Cencora were worth $1,223,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Generate Investment Management Ltd boosted its stake in shares of Cencora by 92.4% during the 4th quarter. Generate Investment Management Ltd now owns 46,508 shares of the company’s stock worth $10,449,000 after acquiring an additional 22,330 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Cencora by 4.4% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,575 shares of the company’s stock worth $6,420,000 after purchasing an additional 1,200 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Cencora by 1.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,597 shares of the company’s stock valued at $6,425,000 after purchasing an additional 312 shares in the last quarter. Ledyard National Bank grew its holdings in Cencora by 64.2% during the fourth quarter. Ledyard National Bank now owns 7,822 shares of the company’s stock valued at $1,757,000 after purchasing an additional 3,058 shares during the period. Finally, Trilogy Capital Inc. raised its stake in shares of Cencora by 5.1% in the fourth quarter. Trilogy Capital Inc. now owns 1,038 shares of the company’s stock worth $233,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COR shares. Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target for the company. UBS Group increased their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Finally, Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,187 shares of company stock valued at $17,790,912. Insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $247.94 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The stock has a 50 day moving average of $239.01 and a 200 day moving average of $236.57. The firm has a market cap of $47.92 billion, a PE ratio of 33.01, a PEG ratio of 1.59 and a beta of 0.49.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%. On average, research analysts expect that Cencora, Inc. will post 15.32 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Friday, February 14th. Cencora’s dividend payout ratio is 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.